少突胶质瘤染色体1p/19q联合缺失与Ki-67表达的关系  

Correlation between combined deletion of chromosome 1p/19q and expression of Ki-67 in mesoglioma

作　　者：孙浩[1] 李卫[1] 

机构地区：[1]广西医科大学附属重庆市肿瘤医院胃肠外科,重庆400030

出　　处：《西南国防医药》2013年第4期366-368,共3页Medical Journal of National Defending Forces in Southwest China

摘　　要：目的观察少突胶质瘤染色体1p/19q联合缺失与Ki-67蛋白表达的相关性,探索预测少突胶质瘤化疗敏感性的分子标记物。方法少突胶质瘤肿瘤组织标本31例作为实验组,少突胶质瘤瘤旁正常脑组织标本13例作为对照组,免疫组化方法检测两组Ki-67蛋白的表达,荧光原位杂交技术检测1p/19q的缺失情况。结果对照组有1例Ki-67表达呈现阳性,占7.7%,实验组有14例Ki-67表达呈现阳性,占45%,两组阳性率差异有统计学意义(P<0.05);对照组无1p/19q缺失,实验组有13例(41.9%)1p/19q联合缺失,其中1p单独缺失2例(6.4%),19q单独缺失1例(3.2%)。结果显示,Ki-67蛋白表达与1p/19q联合缺失显著相关(r=0.13,P<0.05)。结论 Ki-67蛋白表达是预测少突胶质瘤化疗敏感性的潜在分子标记物。Objective To observe the correlation between combined deletion of chromosome 1 p/19q and expression of Ki - 67 in mesoglioma,and to explore the molecular markers forecasting chemosensitivity of mesoglioma. Methods Thirty one tumor tissue speeimens of mesoglioma were selected as experimental group, and 13 specimens of normal brain tissues adjacent to the mesoglioma were chosen as control group. Immunohistochemistry method was used to detect the expression of Ki - 67 protein in both groups, and fluorescence in situ hybridization was carried out to detect the 1 p/19q deletion. Results In the control group, the expression of Ki - 67 was positive in one case, which accounted for 7.7%. In the experimental group, the expression of Ki - 67 was positive in 14 cases, which accounted for 45 %. There were significant differences between the two groups （ P 〈 0.05 ）. The control group had no 1 p/19q deletion, while the experimental group had 13 cases of 1p/19q（41.9% ） combined deletion in which two were lp single deletion（6.4% ） and one was 19q single deletion（3.2% ）. The statistical analysis indicated that there was a correlation between the expression of Ki - 67 protein and the 1p/19q combined deletion（r = 0. 13, P 〈 0.05 ）. Conclusion Ki - 67 protein expression is the potential molecular marker forecasting the chemosensitivity of mesoglioma.

关 键 词：少突胶质瘤 1p 19q KI-67 相关性 

分 类 号：R730.264[医药卫生—肿瘤]